Gap junctional intercellular communication: A new mechanism in pathophysiology of migraine with aura. Therapeutic applications;La communication intercellulaire par l'intermédiaire des jonctions gap: Un nouveau mécanisme dans la physiopathologie de la migraine avec aura. Applications thérapeutiques

Pathologie Biologie

Volumn 60, Issue 6, 2012, Pages 392-398

  Sarrouilhe, D ^a   Dejean, C ^b  

^a UNIVERSITÉ DE POITIERS   (France)

^b CENTRE HOSPITALIER HENRI LABORIT   (France)

Author keywords

Aura; Connexin; Cortical spreading depression; Gap junction; Tonabersat; Trigeminovascular

Indexed keywords

TONABERSAT;

BRAIN CORTEX; CELL COMMUNICATION; DRUG ACTIVITY; ELECTRIC ACTIVITY; ELECTRICAL SYNAPSE; GAP JUNCTION; HEADACHE; HUMAN; INFLAMMATION; MIGRAINE WITH AURA; NEOCORTEX; PATHOPHYSIOLOGY; REVIEW; SPREADING CORTICAL DEPRESSION; TRIGEMINUS GANGLION;

ADOLESCENT; ADULT; ANIMALS; BENZAMIDES; BENZOPYRANS; CELL COMMUNICATION; CORTICAL SPREADING DEPRESSION; GAP JUNCTIONS; HUMANS; MIDDLE AGED; MIGRAINE WITH AURA; NEUROGENIC INFLAMMATION; NEUROGLIA; NEURONS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGEMINAL GANGLION;

EID: 84870388171     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2012.04.002     Document Type: Review

References (41)

1. Haut S.R., Bigal M.E., Lipton R.B. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol 2006, 5:148-157.
2. Headache Classification Committee of the International Headache Society Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 2004, 24(Suppl. 1):9-160. [2nd ed.].
3. Rackauskas M., Neverauskas V., Skeberdis V.A. Diversity and properties of connexin gap junction channels. Medicina 2010, 63:1-12.
4. Hervé J.C., Derangeon M., Théveniau-Ruissy M., Miquerol L., Sarrouilhe D., Gros D. Connexins and junctional channels. Roles in the spreading of cardiac electrical excitation and heart development. Pathol Biol 2008, 56:334-341.
5. Budunova I.V., Williams G.M. Cell culture assays for chemicals with tumor-promoting or tumor-inhibiting activity based on the modulation of intercellular communication. Cell Biol Toxicol 1994, 10:71-116.
6. Hervé J.C., Sarrouilhe D. Connexin-made channels as pharmacological targets. Curr Pharm Des 2005, 11:1941-1958.
7. Nakase T., Naus C.C. Gap junctions and neurological disorders of the central nervous system. Biochim Biophys Acta 2004, 1662:149-158.
8. Orthmann-Murphy J.L., Abrams C.K., Scherer S.S. Gap junctions couple astrocytes and oligodendrocytes. J Mol Neurosci 2007, 35:101-116.
9. Thompson R.J., MacVicar B.A. Connexin and pannexin hemichannels of neurons and astrocytes. Channels 2008, 2:81-86.
10. Zoidl G., Dermietzel R. Gap junctions in inherited human disease. Pflugers Arch 2010, 460:451-466.
11. Rouach N., Avignone E., Même W., Koulakoff A., Venance L., Blomstrand F., et al. Gap junctions and connexin expression in the normal and pathological central nervous system. Biol Cell 2002, 94:457-475.
12. Alldredge B. Clinical connexions. J Clin Pathol 2008, 61:885-890.
13. Olesen J., Burstein R., Ashina M., Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009, 8:679-690.
14. Goadsby P.J., Charbit A.R., Andreou A.P., Akerman S., Holland P.R. Neurobiology of migraine. Neurosci 2009, 161:327-341.
15. Bolay H., Reuter U., Dunn A.K., Huang Z., Boas D.A., Moskowitz M.A. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002, 8:136-142.
16. Chasman D.I., Schurks M., Anttila V., de Vries B., Schminke U., Launer L.J., et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet 2011, 43:695-699.
17. Antilla V., Stefansson H., Kallela M., Todt U., Terwindt G.M., Calafato M.S., et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q221.1. Nat Genet 2010, 42:869-873.
18. Chakravarty A. How triggers trigger acute migraine attacks: a hypothesis. Med Hypothesis 2010, 74:750-753.
19. D'Andrea G., Collavito D., Dalle Carbonare M., Leon A. Migraine with aura: conventional and non conventional treatments. Neurol Sci 2011, 32(Suppl. 1):S121-S129.
20. Aurora S.K., Barrodale P.M., McDonald S.A., Jakubowski M., Burstein R. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache 2009, 49:1001-1004.
21. Edvinsson L., Linde M. New drugs in migraine treatment and propylaxis: telcagepant and topiramate. Lancet 2010, 376:645-655.
22. Evers S., Afra J., Frese A., Goadsby P.J., Linde M., May A., et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009, 16:968-981.
23. Barbanti P., Aurilia C., Egeo G., Fofi L. Migraine prophylaxis: what is new and what we need?. Neurol Sci 2011, 32(Suppl. 1):S111-S115.
24. Olesen J., Ashina M. Emerging migraine treatments and drug targets. Trends Pharmacol Sci 2011, 32:352-359.
25. Wu W., Ye Q., Wang W., Yan L.Y., Wang Q., Xiao H., et al. Amitriptyline calcium currents and intracellular calcium concentration in mouse trigeminal ganglion neurons. Neurosci Lett 2012, 506:307-311.
26. Lampl C., Katsarava Z., Diener H.C., Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005, 76:1730-1732.
27. Marmura M.J., Silberstein S.D. Current understanding and treatment of headache disorders: five new things. Neurology 2011, 76:S31-S35.
28. Bekkelund S.I., Alstadhaug K.B. Migraine prophylactic drugs - something new under the sun. Expert Opin Investig Drugs 2011, 20:1201-1210.
29. Chan W.N., Evans J.M., Hadley M.S., Herdon H.J., Jerman J.C., Parsons A.A., et al. Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)-3,4-dihydro-2,2-dimethyl-2H-benzo[b] pyran-3S-ol as a potential antimigraine agent. Bioorg Med Chem Lett 1999, 9:285-290.
30. Read S.J., Smith M.I., Hunter A.J., Upton N., Parsons A.A. S.B-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia 2000, 20:92-99.
31. Smith M.I., Read S.J., Chan W.N., Thompson M., Hunter A.J., Upton N., et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 2000, 20:546-553.
32. MaassenVanDenBrink A., van den Broek R.W.M., de Vries R., Upton N., Parsons A.A., Saxena P.R. The potential antimigraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia 2000, 20:538-545.
33. Parsons A.A., Bingham S., Raval P., Read S., Thompson M., Upton N. Tonabersat (SB-220453) a novel benzopyran with anticonvulsivant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br J Pharmacol 2001, 132:1549-1557.
34. Damodaram S., Thalakoti S., Freeman S.E., Garrett F.G., Durham P.L. Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling. Headache 2008, 49:5-20.
35. Tvedskov J.F., Iversen H.K., Olesen J. A double-blind study of SB-220453 (tonabersat) in the glyceryltrinitrate (GTN) model of migraine. Cephalalgia 2004, 24:875-882.
36. Goadsby P.J., Ferrari M.D., Csanyi A., Olesen J., Mills J.G. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009, 29:742-750.
37. Hauge A.W., Asghar M.S., Schytz H.W., Christensen K., Olesen J. Effects of tonabersat on migraine with aura: a randomized, double-blind, placebo-controlled crossover study. Lancet Neurol 2009, 8:718-723.
38. Dahlöf C.G.H., Hauge A.W., Olesen J. Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. Cephalalgia 2009, 29:7-16.
39. Silberstein S.D., Schoenen J., Göbel H., Diener H.C., Elkind A.H., Klapper J.A., et al. Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalalgia 2009, 29:17-27.
40. Silberstein S.D. Tonabersat, a novel gap-junction modulator for the prevention of migraine. Cephalalgia 2009, 29:28-35.
41. Kurth T., Chabriat H., Bousser M.G. Migraine and stroke: a complex association with clinical implications. Lancet Neurol 2012, 11:92-100.